FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982648650> ?p ?o ?g. }

• W1982648650 endingPage "707" @default.
• W1982648650 startingPage "702" @default.
• W1982648650 abstract "Summary: Purpose: This study was conducted to determine whether vigabatrin affects in vivo indices of hepatic microsomal enzyme activity and the pharmacokinetics of steroid oral contraceptives in healthy subjects. Methods: Under double-blind conditions, 13 female healthy volunteers received, in random order and with a washout interval of ≤= 4 weeks, two oral 4-week treatments with vigabatrin (VGB) (maintenance dosage, 3,000 mg daily) and placebo, respectively. The clearance and half-life of antipyrine (a broad marker of drug oxidation capacity), the urinary excretion of 6-β-hydroxycortisol (a selective marker of cytochrome CYP3A-mediated oxidation), and the activity of serum γ-glutamyltransferase (a nonspecific index of microsomal enzyme activity) were determined after 3 weeks of each treatment. The single-dose kinetics of a combined oral contraceptive containing 30 μg ethinyl estradiol and 150 μg levonorgestrel were also determined after 3 weeks of treatment by specific radioimmunologic assays. Results: VGB treatment had no influence on antipyrine clearance (28 ± 5.6 vs. 30 ± 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 ± 3.5 vs. 14.1 ± 2.1 h), urinary 6–β-hydroxycortisol excretion (488 ± 164 vs. 470 ± 228 nmol/day), 6-β-hydroxycortisol-to-cortisol concentration ratio (6.8 ± 3.1 vs. 6.1 ± 3.1) and serum γ-glutamyltransferase activity (12 ± 3 vs. 11 ± 3 IUIL). No difference in pharmacokinetic parameters between VGB and placebo sessions were found for ethinyl estradiol (half-life, 12.5 ± 3.2 vs. 13.9 ± 3.2 h; AUC, 874 ± 301 vs. 939 ± 272 ng/L/h) and levonorgestrel (half-life, 17.7 ± 5.2 vs. 23.1 ± 9.8 h; AUC, 27.5 ± 9.6 vs. 30.0 ± 12.0 μg/L/h). Two subjects, however, showed a 50 and a 39% reduction in ethinyl estradiol AUC during VGB treatment. Conclusions: At therapeutic dosages, VGB did not modify in vivo indices of hepatic microsomal enzyme activity and did not interfere significantly with the CYP3A-mediated metabolism of ethinyl estradiol and levonorgestrel. Based on these data, VGB is unlikely to affect consistently the efficacy of steroid oral contraceptives or interact pharmacokinetically with drugs that are eliminated mainly by oxidative pathways, particularly those involving cytochrome CYP3A." @default.
• W1982648650 created "2016-06-24" @default.
• W1982648650 creator A5014610079 @default.
• W1982648650 creator A5030584047 @default.
• W1982648650 creator A5031477185 @default.
• W1982648650 creator A5040883137 @default.
• W1982648650 creator A5044265198 @default.
• W1982648650 creator A5064960484 @default.
• W1982648650 creator A5084891385 @default.
• W1982648650 creator A5086684718 @default.
• W1982648650 date "1997-06-01" @default.
• W1982648650 modified "2023-09-27" @default.
• W1982648650 title "A Double-Blind, Placebo-Controlled Study on the Effect of Vigabatrin on In Vivo Parameters of Hepatic Microsomal Enzyme Induction and on the Kinetics of Steroid Oral Contraceptives in Healthy Female Volunteers" @default.
• W1982648650 cites W1966447707 @default.
• W1982648650 cites W1975404200 @default.
• W1982648650 cites W1978577138 @default.
• W1982648650 cites W1984599271 @default.
• W1982648650 cites W1988858173 @default.
• W1982648650 cites W1990496875 @default.
• W1982648650 cites W2000525046 @default.
• W1982648650 cites W2010494079 @default.
• W1982648650 cites W2011370807 @default.
• W1982648650 cites W2012257102 @default.
• W1982648650 cites W2015245689 @default.
• W1982648650 cites W2025560309 @default.
• W1982648650 cites W2035516110 @default.
• W1982648650 cites W2037313363 @default.
• W1982648650 cites W2039687483 @default.
• W1982648650 cites W2043559003 @default.
• W1982648650 cites W2052628140 @default.
• W1982648650 cites W2065145597 @default.
• W1982648650 cites W2071730519 @default.
• W1982648650 cites W2072715043 @default.
• W1982648650 cites W2074319024 @default.
• W1982648650 cites W2076350936 @default.
• W1982648650 cites W2077006449 @default.
• W1982648650 cites W2121975223 @default.
• W1982648650 cites W7388308 @default.
• W1982648650 doi "https://doi.org/10.1111/j.1528-1157.1997.tb01240.x" @default.
• W1982648650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9186253" @default.
• W1982648650 hasPublicationYear "1997" @default.
• W1982648650 type Work @default.
• W1982648650 sameAs 1982648650 @default.
• W1982648650 citedByCount "54" @default.
• W1982648650 countsByYear W19826486502012 @default.
• W1982648650 countsByYear W19826486502013 @default.
• W1982648650 countsByYear W19826486502014 @default.
• W1982648650 countsByYear W19826486502015 @default.
• W1982648650 countsByYear W19826486502016 @default.
• W1982648650 countsByYear W19826486502017 @default.
• W1982648650 countsByYear W19826486502018 @default.
• W1982648650 countsByYear W19826486502020 @default.
• W1982648650 countsByYear W19826486502022 @default.
• W1982648650 crossrefType "journal-article" @default.
• W1982648650 hasAuthorship W1982648650A5014610079 @default.
• W1982648650 hasAuthorship W1982648650A5030584047 @default.
• W1982648650 hasAuthorship W1982648650A5031477185 @default.
• W1982648650 hasAuthorship W1982648650A5040883137 @default.
• W1982648650 hasAuthorship W1982648650A5044265198 @default.
• W1982648650 hasAuthorship W1982648650A5064960484 @default.
• W1982648650 hasAuthorship W1982648650A5084891385 @default.
• W1982648650 hasAuthorship W1982648650A5086684718 @default.
• W1982648650 hasBestOaLocation W19826486501 @default.
• W1982648650 hasConcept C112705442 @default.
• W1982648650 hasConcept C11824378 @default.
• W1982648650 hasConcept C126322002 @default.
• W1982648650 hasConcept C134018914 @default.
• W1982648650 hasConcept C142724271 @default.
• W1982648650 hasConcept C185592680 @default.
• W1982648650 hasConcept C204787440 @default.
• W1982648650 hasConcept C27081682 @default.
• W1982648650 hasConcept C2779076696 @default.
• W1982648650 hasConcept C2780186607 @default.
• W1982648650 hasConcept C2908647359 @default.
• W1982648650 hasConcept C2986817661 @default.
• W1982648650 hasConcept C526171541 @default.
• W1982648650 hasConcept C62231903 @default.
• W1982648650 hasConcept C71924100 @default.
• W1982648650 hasConcept C98274493 @default.
• W1982648650 hasConcept C99454951 @default.
• W1982648650 hasConceptScore W1982648650C112705442 @default.
• W1982648650 hasConceptScore W1982648650C11824378 @default.
• W1982648650 hasConceptScore W1982648650C126322002 @default.
• W1982648650 hasConceptScore W1982648650C134018914 @default.
• W1982648650 hasConceptScore W1982648650C142724271 @default.
• W1982648650 hasConceptScore W1982648650C185592680 @default.
• W1982648650 hasConceptScore W1982648650C204787440 @default.
• W1982648650 hasConceptScore W1982648650C27081682 @default.
• W1982648650 hasConceptScore W1982648650C2779076696 @default.
• W1982648650 hasConceptScore W1982648650C2780186607 @default.
• W1982648650 hasConceptScore W1982648650C2908647359 @default.
• W1982648650 hasConceptScore W1982648650C2986817661 @default.
• W1982648650 hasConceptScore W1982648650C526171541 @default.
• W1982648650 hasConceptScore W1982648650C62231903 @default.
• W1982648650 hasConceptScore W1982648650C71924100 @default.
• W1982648650 hasConceptScore W1982648650C98274493 @default.
• W1982648650 hasConceptScore W1982648650C99454951 @default.
• W1982648650 hasIssue "6" @default.

• next